Inozyme Pharma Inc

NASDAQ:INZY   3:59:59 PM EDT
24.24
-1.10 (-4.34%)
Earnings Announcements

Inozyme Pharma Reports Third Quarter 2020 Financial Results And Provides Business Highlights

Published: 11/12/2020 11:13 GMT
(INZY) - Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights.
Q3 Loss per Share $1.55.
Q3 Earnings per Share Estimate $-0.51 -- Refinitiv Ibes Data (analyst estimates).
Submitted Cta for Inz-701 for Treatment of Enpp1 Deficiency to United Kingdom Regulatory Agency.
Received Rare Pediatric Disease and Fast Track Designations for Inz-701 for Treatment of Enpp1 Deficiency.
Expect to Initiate Inz-701 Phase 1/2 Clinical Trials for Enpp1 and Abcc6 Deficiencies in First Half of 2021.
Inozyme Pharma - Expect Existing Cash, Cash Equivalents & Investments Sufficient to Fund Operating Expenses & Capex Requirements at Least Into H2 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.55

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.57

More details on our Analysts Page.